Skip to main content

Table 1 Baseline characteristics of patients with ETV-resistance in different rescue therapy groups

From: Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

 

ETV + ADV

TDF

TDF + ETV

N

25

27

20

Age, years

43 (21–64)

44 (20–64)

46 (30–68)

Male, n (%)

20, 80.00%

23, 85.19%

13, 65%

ALT (IU/L)

120.46

61.12

71.00

Normal ALT, n (%)

13, 52.00%

17, 62.96%

10, 50.00%

Bilirubin, mg/dL

18.93

20.67

33.86

Creatinine, mg/dL

78.97

90.62

75.43

HBeAg-positivity, n (%)

17, 67.00%

23, 85.19%

15, 75.00%

HBV DNA (log10 IU/mL)

6.31

5.40

6.23

Previously exposed NUC, n

 LMV

23

14

14

 ADV

0

6

3

 LDT

1

2

1

 LMV + ADV

1

5

2

Duration of NUC treatments (months)

28 (6–110)

26 (6–64)

26 (6–72)

Resistance mutations

 ETV

18

22

17

 Multidrug resistance

7

5

3